New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab

Figures & data

Table 1 Selected trials of bevacizumab treatment in recurrent malignant glioma

Study	Patients	Regimen	Response rate	mPFS	PFS-6	mOS
Ali et al^Citation91	13 MG	(9) aB 5 mg/m^2 q2 wks (4) B 1 mg/m^2 + I 125 mg/m^2 q3 wks	10 (77%)		mTTP 24 wks	27 wks
Friedman et al^Citation101	167 GBM	(85) B (82) B + I	28.2% 37.8%		42.6% 50.3%	9.2 m 8.7 m
Kang et al^Citation95	27 MG	B + I		5.1 m	46%	12.6 m
Kreisl et al^Citation103	48 GBM	B 10 mg/kg q2 wks	17 (35%)	16 wks (12–26)	29% (18–48)	31 wks (21–54)
Mohile et al^Citation105	10 GBM 2 AG	B 10 mg/kg q2 wks + IMRT 6 Gy x5	7 (58%)		76%
Narayana et al^Citation92	37 GBM 24 AG	B 10 mg/kg q2 wks + I 125 mg/m^2 q2 wks or carboplatin AUC6 q4 wks	39/54 (72%)	5 m (2.3–7.7)		9 m (7.6–10.4)
Nghiemphu et al^Citation96	44 GBM	B 5 mg/kg q2 wks + various		4.25 m	41%	9.0 m
Norden et al^Citation97	33 GBM 22 AG	B 10 mg/kg q2 wks + various	34.1%	23.9 wks (17.7–28.3)	42% GBM 32% AG	35.7 wks (27.7–61.4)
Poulson et al^Citation93	27 GBM 22 AG 3 other	B 10 mg/kg + I q2 wks	30% GBM 15% AG	22 wks	40% GBM 33% AG	28 wks GBM 32 wks AG
Vrendenburgh et al^Citation98	35 GBM	(23) B 10 mg/kg + I q2 wks (12) B 15 mg/kg q3 wks + I qwk 4/6 wks	20 (57% (39–74))	24% (18–36)	46% (32–66)	42% (35–60)
Zuniga et al^Citation94	37 GBM 14 AG	B 10 mg/kg + I	25/37 (68%) GBM 11/14 (79%) AG	7.6 m GBM 13.4 m AG	63.7% GBM 78.6% AG	11.5 m GBM NA AG

a Number of patients.

Abbreviations: AG, anaplastic gliomas; B, bevacizumab 10 mg/kg every 2 weeks; B + I, iriotecan 125–340 mg/m² every 2 weeks; GBM, glioblastoma multiforme; IMRT, intensity modulated radiation therapy; MG, malignant glioma; mTTP, median time to tumor progression; m, months; NA, not available; PFS-6, 6-month progression-free survival; mOS, median overall survival; mPFS, median progression-free survical.

Figure 1 A) Axial T1-weighted, post-contrast image of the brain in a patient with glioblastoma multiforme who progressed on temozolomide therapy. B) Response after 2 months of bevacizumab monotherapy.

AliSAMcHaylehWMAhmadABevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 casesJ Neurosurg2008109226827218671639

 PubMed Web of Science ®Google Scholar

FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol200927284733474019720927

 PubMed Web of Science ®Google Scholar

KangTYJinTElinzanoHPeereboomDIrinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safetyJ Neurooncol200889111311818438609

 PubMed Web of Science ®Google Scholar

BatchelorTTGilbertMRSupkoJGPhase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11Neuro Oncol200461212714769136

 PubMed Web of Science ®Google Scholar

MohileNAALLymberisSCKarimiSHouBLGutinPHA pilot study of bevacizumab and stereotactic intensity modulated re-irradiation for recurrent high grade gliomasASCO Meeting Abstracts20072518 Suppl2028

 Google Scholar

NarayanaAKellyPGolfinosJAntiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survivalJ Neurosurg2009110117318018834263

 PubMed Web of Science ®Google Scholar

NghiemphuPLLiuWLeeYBevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experienceNeurology200972141217122219349600

 PubMed Web of Science ®Google Scholar

NordenADYoungGSSetayeshKBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology200834701077978718316689

 PubMed Web of Science ®Google Scholar

PoulsenHSGrunnetKSorensenMBevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumoursActa Oncol2009481525819031176

 PubMed Web of Science ®Google Scholar

VredenburghJJDesjardinsAHerndonJE2ndBevacizumab plus irinotecan in recurrent glioblastoma multiformeJ Clin Oncol200725304722472917947719

 PubMed Web of Science ®Google Scholar

ZunigaRMTorcuatorRJainREfficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecanJ Neurooncol200991332933618953493

 PubMed Web of Science ®Google Scholar